Compare Cassava Sciences Inc (FLNA) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vanguard Value Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Vanguard Value Index Fund ETF trades at $219.8 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 6659.9× Cassava Sciences Inc's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| FLNA | VTV | |
|---|---|---|
Market Cap | $39.40M | $262.40B |
Volume | 759,018 | 3,293,281 |
Sector | Health | — |
52-Week High | $4.64 | $227.51 |
52-Week Low | $0.68 | $182.86 |
Typical Hold Time | 37 Days | 142 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Vanguard Value ETF (VTV) trades at $218.21, down 0.35% on the day amid a bearish technical signal. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $217 and resistance at $219. Recent institutional buying by QRG Capital Management and Blue Edge Capital reflects confidence in value strategies, while news highlights VTV's 2.3% dividend yield and outperformance versus growth ETFs in 2026.
VTV offers exposure to large-cap value stocks with a low 0.03% expense ratio, appealing for income and stability. Risks include prolonged underperformance versus growth sectors and market rotation sensitivity. Analyst sentiment is mixed, balancing dividend appeal against broader market trends. The ETF remains a core holding for value-focused portfolios amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
